PT-141 (Bremelanotide) — 10mg
Research-grade PT-141 (Bremelanotide), a synthetic cyclic heptapeptide melanocortin-receptor agonist (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH) derived from the α-MSH fragment. Studied for activation of melanocortin receptors (MC4R/MC1R) and central nervous system signaling pathways in research models. 10mg lyophilized powder, 99%+ purity verified by Janoshik Analytical via HPLC and mass spectrometry.
For laboratory research use only.
Not for human or veterinary use.
Not intended for diagnosis, treatment, cure, or prevention of any disease.
Use only in controlled laboratory settings by qualified personnel following appropriate safety procedures.
PT-141, also known as bremelanotide, is a cyclic analog of the melanocortin peptide Melanotan II, developed as a non-selective agonist at melanocortin receptors with particular activity at MC4R and MC1R. Unlike its parent compound, bremelanotide acts primarily through central melanocortin pathways rather than peripheral pigmentation pathways, making it a frequent subject in neuroendocrine and behavioral research. The lactam bridge between the Asp and Lys residues constrains the peptide into its bioactive conformation.
BENEFITS
Melanocortin signaling — studied for agonist activity at MC4R and MC1R receptors
Central pathway research — investigated for centrally-mediated effects distinct from peripheral pigmentation
Cyclic stability — lactam-bridged structure constrains the bioactive conformation
α-MSH derived — retains the core melanocortin pharmacophore
Well-characterized — extensively referenced melanocortin research peptide
WHAT RESEARCHERS LOOK AT
Melanocortin receptor (MC4R, MC1R) binding and activation
Central nervous system melanocortin signaling pathways
Behavioral and neuroendocrine research models
Receptor selectivity profiling versus other melanocortin analogs
Structure–activity relationships of the cyclic lactam scaffold
